Corvus Pharmaceuticals (CRVS) Prepaid Assets (2015 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Prepaid Assets of $367000.0 in Q1 2026, down 38.73% quarter-over-quarter from $599000.0 in Q4 2025, and up 321.84% on a YoY basis from $87000.0 in Q1 2025.
Corvus Pharmaceuticals (CRVS) Prepaid Assets (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Prepaid Assets history runs 12 years deep, the most recent figure standing at $367000.0 for Q1 2026.
- In Q1 2026, Prepaid Assets rose 321.84% year-over-year to $367000.0; the TTM figure through Mar 2026 stood at $367000.0 (up 321.84% YoY), while the FY2025 annual figure was $599000.0, up 94.48% from the prior year.
- Prepaid Assets was $367000.0 for Q1 2026 at Corvus Pharmaceuticals, down from $599000.0 in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $1.3 million in Q2 2025 to a low of $62000.0 in Q1 2022.
- Historically, Prepaid Assets has averaged $557882.4 across 5 years, with a median of $599000.0 in 2025.
- The sharpest annual moves came in 2024 and 2025: Prepaid Assets surged 910.14% in 2024, then sank 87.52% in 2025.
- A 5-year view of Prepaid Assets shows it stood at $773000.0 in 2022, then rose by 1.03% to $781000.0 in 2023, then tumbled by 60.56% to $308000.0 in 2024, then soared by 94.48% to $599000.0 in 2025, then plunged by 38.73% to $367000.0 in 2026.
- The last three Prepaid Assets figures came in at $367000.0 (Q1 2026), $599000.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Corvus Pharmaceuticals | 1.01 Bn | 771.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 367,000.00 |
| Dec 31, 2025 | 599,000.00 |
| Sep 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | 87,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Sep 30, 2024 | 633,000.00 |
| Jun 30, 2024 | 240,000.00 |
| Mar 31, 2024 | 697,000.00 |
| Dec 31, 2023 | 781,000.00 |
| Sep 30, 2023 | 214,000.00 |
| Jun 30, 2023 | 371,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Dec 31, 2022 | 773,000.00 |
| Sep 30, 2022 | 1.15 Mn |
| Jun 30, 2022 | 621,000.00 |
| Mar 31, 2022 | 62,000.00 |
| Dec 31, 2021 | 280,000.00 |
| Sep 30, 2021 | 2.15 Mn |
| Jun 30, 2021 | 711,000.00 |